clofibrate has been researched along with cyproterone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Bursch, W; Gerbracht, U; Kraus, P; Putz, B; Reinacher, M; Schulte-Hermann, R; Timmermann-Trosiener, I | 1 |
2 other study(ies) available for clofibrate and cyproterone
Article | Year |
---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver.
Topics: Animals; Body Weight; Carcinogens; Cell Survival; Clofibrate; Cyproterone; Cyproterone Acetate; Female; Glutathione Transferase; Hexachlorocyclohexane; Liver; Liver Neoplasms, Experimental; Nafenopin; Nitrosamines; Organ Size; Phenobarbital; Phenotype; Precancerous Conditions; Propionates; Rats; Rats, Inbred Strains | 1990 |